Please assess the completion status of the following clinical trial:

Trial Title: Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 21 and 65 years of age~* Must meet DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) diagnostic criteria for: Major Depressive Disorder, Bipolar I or II Depressed, Generalized Anxiety Disorder, Social Phobia, Panic Disorder, or Post Traumatic Stress Disorder~* Snaith-Hamilton Pleasure Scale (SHAPS) score ≥ 20~* Reliable and willing to be available for the duration of the study~* Willing and able to give written informed consent to participate~* Able to understand and comply with instructions~* If female of childbearing potential, must agree to use dual methods of contraception and be willing and able to continue contraception for 6 weeks after the last dose of study drug. Females using oral contraception must have started using it at least 2 months prior to the Baseline Visit~* If male of childbearing potential, must have undergone surgical sterilization (such as a vasectomy) or agree to use a condom used with a spermicide during participation in the study and for 1 month afterward~Exclusion Criteria:~* Expected to require hospitalization during the course of the study~* Current/history of a psychotic disorder, current manic or mixed episode, autism spectrum disorders, mental retardation~* Met DSMIV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) criteria for substance abuse within the last 3 months or substance dependence within the last 6 months, excluding caffeine and/or nicotine~* History of unstable or untreated serious medical condition based on physician evaluation, medical history, and screening laboratory testing~* Active suicidal intent or plan, or history of attempt within the past 3 months based on physician evaluation and Columbia Suicide Severity Rating Scale (C-SSRS)~* Use of any antidepressant, antipsychotic, anxiolytic, anticonvulsant, mood stabilizing, muscle relaxant, centrally acting antihistaminergic, stimulant or insomnia medications (See Appendix 2) within 5 half-lives of baseline or at any time during after baseline~* Use of any medication that is primarily metabolized by Cytochrome P450 2C8 within 14 days of baseline or at any time during the study. This includes: Cerivastatin, Paclitaxel, Repaglinide, Sorafenib, Rosiglitazone, Trimethoprim, Amodiaquine, Morphine, Amiodarone, Cabazitaxel, Carbamazepine, Chloroquine, Ibuprofen, Trepostinil, Torsemide.~* Any contraindications to the magnetic resonance imaging procedures~* Positive urine drug screen at any time during the study~* Use of any investigational medication within 3 months prior to the start of this study or scheduled to receive an investigational drug other than the study drug during the course of this study~* Known hypersensitivity to CERC-501 (formerly known as LY2456302)~* History of severe allergies or multiple adverse drug reactions~* History of gastric disease (including peptic ulcer disease, gastritis, upper GI bleeding, or any GI precancerous condition), current clinically evident gastrointestinal complaints, or positive urea breath test~* Current use of a proton pump inhibitor or histamine 2 blocker, or a history of chronic NSAID (nonsteroidal anti-inflammatory drug) use.~* History of use of Salvia divinorum or use of Salvia divinorum at any time during the study.~* Any other condition that in the opinion of the investigator would preclude participation in the study~* Any smoking of cigarettes or use of other nicotine containing products within the last month or at any time during the study~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CERC-501 (Type: EXPERIMENTAL): Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Oral daily administration of 10 mg placebo for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).